229 related articles for article (PubMed ID: 32777360)
1. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Brochard J; Morio F; Mahe J; Le Pape P; Guimard T; Mahe B; Leterrier M; Morrier M; Raffi F; Boutoille D
Med Mal Infect; 2020 Nov; 50(8):742-745. PubMed ID: 32777360
[TBL] [Abstract][Full Text] [Related]
2. [Severe systemic vasculitis induced by ibrutinib].
Fenot M; Woaye Hune P; Vigouroux S; Veyrac G; Poiraud C
Rev Med Interne; 2024 Jan; 45(1):13-16. PubMed ID: 37951781
[TBL] [Abstract][Full Text] [Related]
3. Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies.
Tham K; Prelewicz S; deHoll S; Stephens DM; Gomez CA
Am J Health Syst Pharm; 2024 Feb; 81(4):112-119. PubMed ID: 37675967
[TBL] [Abstract][Full Text] [Related]
4. [Disseminated cryptococcosis during ibrutinib treatment for chronic lymphocytic leukemia].
Kumekawa H; Watanabe D; Tamura K; Mizuchi D
Rinsho Ketsueki; 2022; 63(1):62-65. PubMed ID: 35135954
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
[TBL] [Abstract][Full Text] [Related]
6. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases.
Santoro RC; Falbo M; Levato L; Iannaccaro P; Prejanò S
Blood Coagul Fibrinolysis; 2021 Mar; 32(2):159-161. PubMed ID: 33273263
[TBL] [Abstract][Full Text] [Related]
8. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
9. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
Mehraban Far P; Rullo J; Farmer J; Urton T
Ocul Immunol Inflamm; 2022 May; 30(4):1005-1008. PubMed ID: 33539715
[TBL] [Abstract][Full Text] [Related]
10. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
[TBL] [Abstract][Full Text] [Related]
11. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.
Brener ZZ; Brener H; Losev A
J Oncol Pharm Pract; 2020 Oct; 26(7):1735-1737. PubMed ID: 32054411
[TBL] [Abstract][Full Text] [Related]
13. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
DiSogra KY; Tran T; Arnall JR; Janes A; Moore DC; Park SI
J Oncol Pharm Pract; 2021 Jul; 27(5):1265-1269. PubMed ID: 33106104
[TBL] [Abstract][Full Text] [Related]
15. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S
Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147
[TBL] [Abstract][Full Text] [Related]
16. Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration.
Walker C; Horowitz A; Nooruddin Z; Frei CR
J Oncol Pharm Pract; 2024 Jun; 30(4):673-677. PubMed ID: 37309168
[TBL] [Abstract][Full Text] [Related]
17. Invasive fungal infections in patients treated with Bruton's tyrosine kinase inhibitors.
Dunbar A; Joosse ME; de Boer F; Eefting M; Rijnders BJA
Neth J Med; 2020 Sep; 78(5):294-296. PubMed ID: 33093256
[TBL] [Abstract][Full Text] [Related]
18. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
19. Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.
Spaner DE; Luo Y; Wang G; Gallagher J; Tsui H; Shi Y
Cancer Med; 2021 Dec; 10(24):8789-8798. PubMed ID: 34791813
[TBL] [Abstract][Full Text] [Related]
20. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
Peri AM; Rossio R; Tafuri F; Benzecry V; Grancini A; Reda G; Bandera A; Peyvandi F
Ann Hematol; 2019 Dec; 98(12):2847-2849. PubMed ID: 31741032
[No Abstract] [Full Text] [Related]
[Next] [New Search]
